The Pragmatica-Lung Study (S2302)
In collaboration with MultiCare Institute for Research & Innovation, we have opened enrollment for the S2302 Pragmatica-Lung trial.
The Pragmatica-Lung Study (S2302) is focused on evaluating the effectiveness of a two-drug combination non-chemotherapy treatment versus standard care for patients with advanced non-small cell lung cancer (NSCLC).
What makes this trial unique is the user-friendly design, which simplifies participation for institutions and reduces barriers to patient eligibility. Our hope is that these studies serve two-fold: yielding valuable insights into lung and breast cancer research today, and establishing a precedent for the design, accessibility, and the diversity of patient populations for future trials.
In partnership with MultiCare, Northwest Medical Specialties, the Southwest Oncology Group (SWOG), and other medical institutions at the forefront of cancer care and research, we are collectively working towards a future where groundbreaking treatments and research are accessible to all who need it.